Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.
Latest press release
ExpreS2ion will participate in key investor and industry events in October 2021
ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor and industry events in October. These include events hosted by HC Andersen Capital as well as the World Vaccine Congress and BIO-EUROPE.Read more